rilonacept

Also known as IL-1 Trap, Interleukin-1 Trap, Arcalyst, interleukin-1 (IL-1) trap, ARCALYST

Rilonacept, sold under the brand name Arcalyst, is a medication used to treat cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome, and Muckle–Wells syndrome; deficiency of interleukin-1 receptor antagonist; and recurrent pericarditis. Rilonacept is an interleukin 1 inhibitor.

Key facts

Drug.N: 2400
Drug.O: 2670
Drug.S: 74
Drug.Verifiedfields: changed
Drug.verifiedrevid: 464382495
Drug.tradename: Arcalyst
Drug.licence_EU: yes
Drug.DailyMedID: Rilonacept
Drug.routes_of_administration: Subcutaneous
Drug.ATC_prefix: L04
Drug.ATC_suffix: AC04
Drug.legal_US: Rx-only
Drug.legal_EU: Rx-only
Drug.CAS_number: 501081-76-1
Drug.DrugBank: DB06372
Drug.ChemSpiderID: none
Drug.UNII: 8K80YB5GMG
Drug.KEGG: D06635

via Wikipedia infobox

Research

320 papers

Rilonacept.2012
Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis.The New England journal of medicine · 2021
Rilonacept: A Newly Approved Treatment for Recurrent Pericarditis.The Annals of pharmacotherapy · 2022
Rilonacept for the treatment of recurrent pericarditis.Expert opinion on biological therapy · 2022
Rilonacept (Interleukin-1 Inhibition) for the Treatment of Pericarditis.Current cardiology reports · 2022

via PubMed

~1 min read

Encyclopedic overview

2 sections

Contents

References
External links

Rilonacept is a dimeric fusion protein consisting of the ligand-binding domains of the extracellular portions of the human interleukin-1 receptor component (IL-1R1) and IL-1 receptor accessory protein (IL-1RAcP) linked in-line to the fragment-crystallizable portion (Fc region) of human IgG1 that binds and neutralizes IL-1.

Excerpted from Wikipedia’s “rilonacept” article, available under the CC BY-SA 4.0 licence.

Available in 15 languages

via Wikidata sitelinks · CC0